Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)

3 Views
Published
The committee will discuss new drug application 215484, for the Nrf2 activator, bardoxolone methyl capsules, submitted by Reata Pharmaceuticals, Inc. The proposed indication is to slow the progression of chronic kidney disease caused by Alport syndrome in patients 12 years of age and older.
Category
Management
Be the first to comment